(Q24250210)

https://api.crossref.org/works/10.1002%2F14651858.CD003280

Risk of cancer from azathioprine therapy in multiple sclerosis: a case-control study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003280

Distal acquired demyelinating symmetric neuropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003280

Azathioprine toxicity in neuromuscular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003280

Chronic inflammatory demyelinating polyradiculoneuropathy. A clinical and electrophysiological study of 92 cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003280

A randomized double-blind trial of prednisolone alone or with azathioprine in myasthenia gravis. Myasthenia Gravis Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003280

PRISMS-4: Long-term efficacy of interferon-beta-1a in relapsing MS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003280

Interobserver agreement for the assessment of handicap in stroke patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003280

Progressive Polyradiculoneuropathy: Treatment with Azathioprine

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003280

Randomized trial of interferon beta-1a in chronic inflammatory demyelinating polyradiculoneuropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003280

Clinicopathologic findings and prognosis of chronic inflammatory demyelinating polyneuropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003280

High-dose cyclophosphamide without stem-cell rescue for refractory CIDP

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003280

Pulse cyclophosphamide therapy in chronic inflammatory demyelinating polyneuropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003280

Improvement following interferon-alpha 2A in chronic inflammatory demyelinating polyneuropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003280

Subacute Idiopathic Demyelinating Polyradiculoneuropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003280

Prevalence of monoclonal protein in peripheral neuropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003280

Chronic nephrotoxicity complicating cyclosporine treatment of chronic inflammatory demyelinating polyradiculoneuropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003280

Interferon-beta1a in chronic inflammatory demyelinating polyneuropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003280

Multifocal demyelinating neuropathy with persistent conduction block

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003280

Randomized controlled trial of IVIg in untreated chronic inflammatory demyelinating polyradiculoneuropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003280

Clinical spectrum of chronic acquired demyelinating polyneuropathies

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003280

7 January 2021

Randomized controlled trial of intravenous immunoglobulin versus oral prednisolone in chronic inflammatory demyelinating polyradiculoneuropathy.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003280

7 January 2021

Human diabetic endoneurial sorbitol, fructose, and myo-inositol related to sural nerve morphometry

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003280

7 January 2021

Chronic relapsing (Dysimmune) polyneuropathy: Pathogenesis and treatment

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003280

7 January 2021

A plasma exchange versus immune globulin infusion trial in chronic inflammatory demyelinating polyradiculoneuropathy.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003280

7 January 2021

Guillain-Barré syndrome and chronic inflammatory demyelinating polyneuropathy: immune mechanisms and update on current therapies

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003280

7 January 2021

Cyclosporin A in resistant chronic inflammatory demyelinating polyradiculoneuropathy.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003280

7 January 2021

Multifocal acquired demyelinating sensory and motor neuropathy: the Lewis-Sumner syndrome

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003280

7 January 2021

Chronic inflammatory demyelinating polyneuropathy after treatment with interferon-alpha

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003280

7 January 2021

Treatment of chronic relapsing inflammatory demyelinating polyneuropathy by cyclosporin A and plasma exchange. A case report

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003280

7 January 2021

Focal cranial nerve involvement in chronic inflammatory demyelinating polyneuropathy: clinical and MRI evidence of peripheral and central lesions

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003280

7 January 2021

Improvement following interferon beta in chronic inflammatory demyelinating polyradiculoneuropathy

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003280

7 January 2021

Chronic relapsing polyneuritis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003280

7 January 2021

Mycophenolate (CellCept) treatment of myasthenia gravis, chronic inflammatory polyneuropathy and inclusion body myositis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003280

7 January 2021

Treatment of polyneuropathy with azathioprine

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003280

7 January 2021

Randomised double-blind placebo-controlled study of interferon β-1a in relapsing/remitting multiple sclerosis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003280

7 January 2021

Multifocal motor neuropathy.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003280

7 January 2021

Plasma exchange in chronic inflammatory demyelinating polyradiculoneuropathy

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003280

7 January 2021

Long-term follow-up of patients with chronic inflammatory demyelinating polyradiculoneuropathy, without and with monoclonal gammopathy

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003280

7 January 2021

Focal upper limb demyelinating neuropathy

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003280

7 January 2021

Plasma-exchange therapy in chronic inflammatory demyelinating polyneuropathy. A double-blind, sham-controlled, cross-over study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003280

7 January 2021

Intravenous immunoglobulin treatment in chronic inflammatory demyelinating polyneuropathy. A double-blind, placebo-controlled, cross-over study.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003280

7 January 2021

Recurrent polyneuropathies and their corticosteroid treatment; with five-year observations of a placebo-controlled case treated with corticotrophin, cortisone, and prednisone

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003280

7 January 2021

Cyclosporin A in the treatment of chronic demyelinating polyradiculoneuropathy

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003280

7 January 2021

Involvement of the central nervous system in chronic inflammatory demyelinating polyneuropathy: a clinical, electrophysiological and magnetic resonance imaging study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003280

7 January 2021

"Chronic sensory demyelinating neuropathy": chronic inflammatory demyelinating polyneuropathy presenting as a pure sensory neuropathy

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003280

7 January 2021

Intravenous immunoglobulin treatment in patients with chronic inflammatory demyelinating polyneuropathy: a double blind, placebo controlled study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003280

7 January 2021

Treatment of chronic inflammatory demyelinating polyneuropathy with cyclosporin-A

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003280

7 January 2021

Chronic inflammatory demyelinating polyneuropathy during treatment with interferon-alpha.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003280

7 January 2021

Chronic motor neuropathies: response to interferon-beta1a after failure of conventional therapies

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003280

7 January 2021

Chronic inflammatory demyelinating polyradiculoneuropathy: a prevalence study in south east England

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003280

7 January 2021

Clinimetric evaluation of a new overall disability scale in immune mediated polyneuropathies

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003280

7 January 2021